Literature DB >> 29226532

Low molecular weight heparin for the prevention of severe preeclampsia: where next?

Kelsey McLaughlin1,2, Ralph R Scholten3, John D Parker2, Enrico Ferrazzi4, John C P Kingdom1,3.   

Abstract

Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  anticoagulants; cardiology; clinical trials; gynaecology/obstetrics; hypertension; pregnancy

Mesh：

Substances：

Year:  2018        PMID： 29226532      PMCID： PMC5867115          DOI： 10.1111/bcp.13483

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  56 in total

1.  Persistent Maternal Cardiac Dysfunction After Preeclampsia Identifies Patients at Risk for Recurrent Preeclampsia.

Authors:  Herbert Valensise; Damiano Lo Presti; Giulia Gagliardi; Grazia Maria Tiralongo; Ilaria Pisani; Gian Paolo Novelli; Barbara Vasapollo
Journal:  Hypertension       Date:  2016-02-22       Impact factor: 10.190

2.  Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial.

Authors:  R D'Souza; S Keating; M Walker; S Drewlo; J Kingdom
Journal:  Placenta       Date:  2014-07-24       Impact factor: 3.481

Review 3.  Maternal cardiac function in preeclampsia.

Authors:  Karen Melchiorre; Basky Thilaganathan
Journal:  Curr Opin Obstet Gynecol       Date:  2011-12       Impact factor: 1.927

4.  Strategy for standardization of preeclampsia research study design.

Authors:  Leslie Myatt; Christopher W Redman; Anne Cathrine Staff; Stefan Hansson; Melissa L Wilson; Hannele Laivuori; Lucilla Poston; James M Roberts
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

5.  Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor.

Authors:  Y Yinon; E Ben Meir; L Margolis; S Lipitz; E Schiff; S Mazaki-Tovi; M J Simchen
Journal:  Placenta       Date:  2014-12-20       Impact factor: 3.481

6.  Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease.

Authors:  Herbert Valensise; Barbara Vasapollo; Giulia Gagliardi; Gian Paolo Novelli
Journal:  Hypertension       Date:  2008-09-29       Impact factor: 10.190

7.  Fetal growth and body proportion in preeclampsia.

Authors:  Svein Rasmussen; Lorentz M Irgens
Journal:  Obstet Gynecol       Date:  2003-03       Impact factor: 7.661

8.  Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction.

Authors:  F Crispi; E Llurba; C Domínguez; P Martín-Gallán; L Cabero; E Gratacós
Journal:  Ultrasound Obstet Gynecol       Date:  2008-03       Impact factor: 7.299

9.  IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?

Authors:  C W Redman; I L Sargent; A C Staff
Journal:  Placenta       Date:  2014-01-11       Impact factor: 3.481

10.  Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia.

Authors:  Augustine Rajakumar; Ana Sofia Cerdeira; Sarosh Rana; Zsuzsanna Zsengeller; Lia Edmunds; Arun Jeyabalan; Carl A Hubel; Isaac E Stillman; Samir M Parikh; S Ananth Karumanchi
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190
View more
  3 in total

1.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

Review 2.  Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

Authors:  E Pierik; Jelmer R Prins; Harry van Goor; Gustaaf A Dekker; Mohamed R Daha; Marc A J Seelen; Sicco A Scherjon
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

3.  Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.

Authors:  Jovian M Wat; Krista Hawrylyshyn; Dora Baczyk; Iain R Greig; John C Kingdom
Journal:  Biol Reprod       Date:  2018-11-01       Impact factor: 4.285
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.